A1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial) - 12/08/11
, Mark D. Shepherd, MD b, Franklin C. Coulter, MD c, Anuj Bhargava, MD d, Jason Brett, MD e, Pei-Ling Chu, PhD e, Bruce S. Trippe, MD fAbstract |
Purpose |
To study glycemic control and hypoglycemia development upon initiation of insulin through a self-titration schedule in a 24-week trial, conducted with 4875 insulin-naïve patients with poorly controlled type 2 diabetes, predominantly in a primary care setting.
Methods |
Subjects initiated twice-daily biphasic insulin aspart 70/30 with 6 units prebreakfast and 6 units presupper, self-titrating according to self-measured blood glucose values. Subjects were randomized (1:1:1) to telephone counseling provided by a registered dietician: no counseling (NC), 1 counseling session (1C), or 3 sessions (3C).
Results |
Mean baseline HbA1c (9.9% across groups) decreased
2.5% to 7.49%±1.48, 7.48%±1.50, and 7.44%±1.46 in the NC, 1C, and 3C groups, respectively. Within these groups, a hemoglobin A1c (HbA1c) value <7% was achieved by 40.2%, 41.6%, and 41.8% of subjects, respectively. Eight-point blood glucose profiles were substantially improved from baseline for all groups. Hypoglycemia was experienced by 10.2%-11.4% of the subjects in each group. Rates of minor and major hypoglycemia were low but decreased as dietary counseling increased (minor hypoglycemia: 56 vs 50 vs 45 episodes per 100 patient-years; major hypoglycemia, 9 vs 6 vs 4 episodes per 100 patient-years, for the NC vs 1C vs 3C groups, respectively; P <.001, 3C vs NC). Weight increased by 3.13, 3.40, and 2.88 kg for the NC, 1C, and 3C groups, respectively.
Conclusion |
In the primary care setting, self-titration of biphasic insulin aspart 70/30 was effective in achieving recommended HbA1c goals even with minimal dietary counseling.
Le texte complet de cet article est disponible en PDF.Keywords : Biphasic insulin aspart 70/30, Hypoglycemia, Insulin self-titration, NovoLog® Mix 70/30
Plan
| Funding: This clinical study was supported by Novo Nordisk Inc., Princeton, NJ. |
|
| Conflict of Interest: The following disclosures address potential conflicts of interest by the authors for the manuscript: David S. Oyer is on the speaker bureau and advisory board for Novo Nordisk Inc., and on the speaker's bureaus for Amylin, Lilly, Merck, Sanofi-Aventis, and Novartis. Mark D. Shepherd is affiliated with the sponsoring organization, Novo Nordisk Inc. as a consultant, national speaker, researcher, recipient of grant support, and a shareholder in the company. Franklin C. Coulter is on the speaker bureau for Novo Nordisk Inc. for Novolog® Mix 70/30 and for Levemir®. He also is on the advisory board for Novolog® Mix 70/30. Anuj Bhargava is on the speaker's bureaus for Novo Nordisk Inc., Sanofi Aventis, Pfizer, Amylin Pharmaceuticals, Abbott Laboratories, Medtronic and Takeda Pharmaceuticals. He has been or is involved in research studies with Novo Nordisk Inc., Pfizer, Amylin Pharmaceuticals, Lilly, Sanofi Aventis and Merck. Jason Brett and Pei-Ling Chu are employees of Novo Nordisk Inc. Bruce S. Trippe has been on the speaker's bureaus for Astra Zenica, Glaxo Smith Kline, Novartis, Merck, Schering Plough, Sanofi Aventis, Novo Nordisk Inc., and Abbott; he has received grant support from Novo Nordisk Inc. for clinical research. |
|
| Authorship: The work submitted in this manuscript is original and all authors meet the criteria for authorship, including access to the data, a role in performing the research, writing the manuscript, and acceptance of responsibility for the scientific content of the manuscript. |
Vol 122 - N° 11
P. 1043-1049 - novembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
